Advisory Committees: FDA Gets Out Of The Redaction Business
This article was originally published in The Rose Sheet
Executive Summary
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.
You may also be interested in...
US FDA May Change Advisory Committee Planning, Member Screening
Departing Commissioner says that special government employee procedure especially is in need of reform.
FDA Advisory Committee Disclosures Sought In Public Citizen Suit
Unredacted curricula vitae could disclose privately funded grants, pending clinical trials, and pending publications among other information.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.